Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T68536
|
||||
Former ID |
TTDS00308
|
||||
Target Name |
Tubulin beta
|
||||
Synonyms |
Beta-tubulin; Congopain; Cruzaine; Cysteine proteinase cruzipain; Major cysteine proteinase; Tubulin beta-1 chain
|
||||
Target Type |
Successful
|
||||
Disease | Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0] | ||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Glioblastoma multiforme [ICD9: 191; ICD10: C71] | |||||
Mesothelioma [ICD9: 163; ICD10: C45] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Worm infections [ICD9: 120-129; ICD10: B65-B83] | |||||
Function |
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
|
||||
BioChemical Class |
Tubulin family
|
||||
Target Validation |
T68536
|
||||
EC Number |
EC 3.4.22.51
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Albendazole | Drug Info | Approved | Worm infections | [536135] |
Mebendazole | Drug Info | Approved | Worm infections | [536224] | |
Oral paclitaxel | Drug Info | Approved | Cancer | [551871] | |
Taxol | Drug Info | Approved | Breast carcinoma | [530307] | |
Vincristine | Drug Info | Approved | Acute lymphoblastic leukemia | [536556], [541865] | |
Vindesine | Drug Info | Approved | Acute lymphoblastic leukemia | [536361], [551871] | |
Liposomal encapsulated paclitaxel (LEP) | Drug Info | Phase 3 | Cancer | [551035] | |
Sphingosome Encapsulated Vinorelbine | Drug Info | Phase 3 | Solid tumours | [522410] | |
Batabulin | Drug Info | Phase 2/3 | Cancer | [521550] | |
ABT-751 | Drug Info | Phase 2 | Solid tumours | [521967] | |
BNC-105 | Drug Info | Phase 2 | Mesothelioma | [547995] | |
DOLASTATIN-10 | Drug Info | Phase 2 | Cancer | [521453] | |
Lexibulin iv infusion | Drug Info | Phase 2 | Glioblastoma multiforme | [522301] | |
Plinabulin | Drug Info | Phase 2 | Non-small cell lung cancer | [549687] | |
T-607 | Drug Info | Phase 2 | Cancer | [521548] | |
Verubulin | Drug Info | Phase 2 | Solid tumours | [523339] | |
ZD-6126 | Drug Info | Phase 2 | Cancer | [521567] | |
BAL-101553 | Drug Info | Phase 1/2 | Cancer | [525257] | |
1069C | Drug Info | Phase 1 | Cancer | [534331] | |
ABI-011 | Drug Info | Phase 1 | Solid tumours | [523113] | |
ALB-109564(a) | Drug Info | Phase 1 | Solid tumours | [522388] | |
CKD-516 | Drug Info | Phase 1 | Solid tumours | [523842] | |
DAVLB-HYDRAZIDE | Drug Info | Phase 1 | Cancer | [530726] | |
NSC-639829 | Drug Info | Phase 1 | Cancer | [544019] | |
Simotaxel | Drug Info | Phase 1 | Cancer | [521789] | |
STA-5312 | Drug Info | Phase 1 | Cancer | [521784] | |
Tasidotin hydrochloride | Drug Info | Phase 1 | Cancer | [528421] | |
KOS-1803 | Drug Info | Preclinical | Cancer | [548297] | |
CEMADOTIN HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Cancer | [546200] | |
Epothilone D | Drug Info | Discontinued in Phase 2 | Breast cancer | [547385] | |
RHIZOXIN | Drug Info | Discontinued in Phase 2 | Breast cancer | [544988] | |
S-12363 | Drug Info | Discontinued in Phase 2 | Cancer | [544756] | |
Denibulin | Drug Info | Discontinued in Phase 1 | Cancer | [548126] | |
Modulator | 1069C | Drug Info | [550941], [551871] | ||
ABI-011 | Drug Info | ||||
ABT-751 | Drug Info | [1572591] | |||
ALB-109564(a) | Drug Info | ||||
APH-0911 | Drug Info | [543674] | |||
ARC-200 | Drug Info | [543674] | |||
BNC-105 | Drug Info | ||||
CEMADOTIN HYDROCHLORIDE | Drug Info | [534776], [551871] | |||
DAVLB-HYDRAZIDE | Drug Info | [544311], [551871] | |||
IDN-5390 | Drug Info | [543674] | |||
Isoquinoline alkaloids | Drug Info | [543674] | |||
Liposomal encapsulated paclitaxel (LEP) | Drug Info | [526031], [530307] | |||
NSC-639829 | Drug Info | [526117], [551871] | |||
Oral paclitaxel | Drug Info | [526031], [530307] | |||
Plinabulin | Drug Info | ||||
S-12363 | Drug Info | [550022] | |||
Sphingosome Encapsulated Vinorelbine | Drug Info | [529890] | |||
Taxol | Drug Info | [530307] | |||
Verubulin | Drug Info | ||||
Vincristine | Drug Info | [556264] | |||
XN-0502 | Drug Info | [543674] | |||
Inhibitor | 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene | Drug Info | [528474] | ||
2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene | Drug Info | [528474] | |||
2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde | Drug Info | [534765] | |||
2-amino-3,4',5-trimethoxy-(Z)-stillbene | Drug Info | [528474] | |||
2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one | Drug Info | [525604] | |||
2-m-Tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol | Drug Info | [527276] | |||
2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol | Drug Info | [525946] | |||
2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol | Drug Info | [525450] | |||
2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
3,4',5-trimethoxy-(Z)-stilbene | Drug Info | [528474] | |||
3,4,4',5-tetramethoxy-(Z)-stilbene | Drug Info | [528474] | |||
3-bromo-4,4',5-trimethoxy-(Z)-stilbene | Drug Info | [528474] | |||
5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
6-ile-ustiloxin | Drug Info | [528306] | |||
6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [534469] | |||
BAL-101553 | Drug Info | [533035] | |||
Batabulin | Drug Info | [526170] | |||
CENTAUREIDIN | Drug Info | [534652] | |||
CKD-516 | Drug Info | [532537] | |||
COLCHINOL | Drug Info | [527777] | |||
COMBETASTATIN | Drug Info | [534795] | |||
Denibulin | Drug Info | [544311] | |||
DOLASTATIN-10 | Drug Info | [528306] | |||
Epothilone D | Drug Info | [551393] | |||
GNF-PF-117 | Drug Info | [534009] | |||
Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate | Drug Info | [527999] | |||
KOS-1803 | Drug Info | [543674] | |||
Lexibulin iv infusion | Drug Info | [550425] | |||
MR-22388 | Drug Info | [526982] | |||
MYOSEVERIN | Drug Info | [526222] | |||
N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide | Drug Info | [528428] | |||
NSC-106970 | Drug Info | [534652] | |||
NSC-664171 | Drug Info | [534600] | |||
NSC-679036 | Drug Info | [534469] | |||
ON-24160 | Drug Info | [543674] | |||
PHENSTATIN | Drug Info | [526346] | |||
RHIZOXIN | Drug Info | [528337] | |||
RTA-301 | Drug Info | [543674] | |||
Simotaxel | Drug Info | [543674] | |||
STA-5312 | Drug Info | [550066], [551871] | |||
T-607 | Drug Info | [551628] | |||
THIOCOLCHICINE | Drug Info | [534060] | |||
TL-1892 | Drug Info | [543674] | |||
USTILOXIN A | Drug Info | [528306] | |||
Ustiloxin D | Drug Info | [528306] | |||
Ustiloxin F | Drug Info | [528306] | |||
ZD-6126 | Drug Info | [529270] | |||
Binder | Albendazole | Drug Info | [537193] | ||
Mebendazole | Drug Info | [537193] | |||
Tasidotin hydrochloride | Drug Info | [536891] | |||
Vindesine | Drug Info | [536411], [536504] | |||
Pathways | |||||
KEGG Pathway | Phagosome | ||||
Gap junction | |||||
Pathogenic Escherichia coli infection | |||||
NetPath Pathway | FSH Signaling Pathway | ||||
TCR Signaling Pathway | |||||
EGFR1 Signaling Pathway | |||||
PANTHER Pathway | Cytoskeletal regulation by Rho GTPase | ||||
Huntington disease | |||||
Reactome | Regulation of PLK1 Activity at G2/M Transition | ||||
Loss of Nlp from mitotic centrosomes | |||||
Recruitment of mitotic centrosome proteins and complexes | |||||
Loss of proteins required for interphase microtubule organization?from the centrosome | |||||
Anchoring of the basal body to the plasma membrane | |||||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | ||||
Pathogenic Escherichia coli infection | |||||
Mitotic G2-G2/M phases | |||||
References | |||||
Ref 521453 | ClinicalTrials.gov (NCT00003677) Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | ||||
Ref 521548 | ClinicalTrials.gov (NCT00054249) T900607 in Treating Patients With Gastroesophageal Junction Cancer. U.S. National Institutes of Health. | ||||
Ref 521550 | ClinicalTrials.gov (NCT00057382) T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients. U.S. National Institutes of Health. | ||||
Ref 521567 | ClinicalTrials.gov (NCT00065572) Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV). U.S. National Institutes ofHealth. | ||||
Ref 521784 | ClinicalTrials.gov (NCT00276913) A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 521789 | ClinicalTrials.gov (NCT00277836) Study Evaluating MST-997 in Advanced Malignant Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 521967 | ClinicalTrials.gov (NCT00436852) ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment. U.S. National Institutes of Health. | ||||
Ref 522301 | ClinicalTrials.gov (NCT00664378) Efficacy Study of CYT997 in Multiple Myeloma. U.S. National Institutes of Health. | ||||
Ref 522388 | ClinicalTrials.gov (NCT00724100) A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 522410 | ClinicalTrials.gov (NCT00737867) Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
Ref 523113 | ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health. | ||||
Ref 523339 | ClinicalTrials.gov (NCT01285414) Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme. U.S. National Institutes of Health. | ||||
Ref 523842 | ClinicalTrials.gov (NCT01560325) Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers. U.S. National Institutes of Health. | ||||
Ref 525257 | ClinicalTrials.gov (NCT02490800) Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors. | ||||
Ref 528421 | Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.Clin Cancer Res. 2006 Sep 1;12(17):5207-15. | ||||
Ref 530307 | Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. | ||||
Ref 530726 | The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 1991 May 1;51(9):2286-90. | ||||
Ref 534331 | Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer. 1997;75(4):608-13. | ||||
Ref 536135 | Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. | ||||
Ref 536224 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 536556 | Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry. 2007 Dec 25;46(51):14899-906. Epub 2007 Dec 4. | ||||
Ref 541865 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785). | ||||
Ref 544019 | Phase I Study of Continuous Weekly Dosing of Dimethylamino Benzoylphenylurea (BPU) in Patients with Solid Tumours. Eur J Cancer. 2007 January; 43(1): 78-86. | ||||
Ref 544756 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000879) | ||||
Ref 544988 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001808) | ||||
Ref 546200 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006853) | ||||
Ref 547385 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015773) | ||||
Ref 547995 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021025) | ||||
Ref 548126 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022182) | ||||
Ref 525450 | Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12.The synthesis and evaluation of temperature sensitive tubulin toxins. | ||||
Ref 525604 | J Med Chem. 1999 Oct 7;42(20):4081-7.Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. | ||||
Ref 525946 | Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4.Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. | ||||
Ref 526031 | The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5312-6. Epub 2001 Apr 17. | ||||
Ref 526170 | Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605. | ||||
Ref 526222 | J Med Chem. 2001 Dec 20;44(26):4497-500.Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. | ||||
Ref 526346 | J Med Chem. 2002 Jun 6;45(12):2534-42.Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. | ||||
Ref 526982 | J Med Chem. 2004 Mar 11;47(6):1448-64.Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. | ||||
Ref 527276 | J Med Chem. 1992 Mar 20;35(6):1058-67.Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions. | ||||
Ref 527777 | Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9. Epub 2005 Sep 28.Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. | ||||
Ref 527999 | J Med Chem. 2006 Feb 9;49(3):947-54.New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. | ||||
Ref 528306 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. Epub 2006 Jul 11.Total synthesis and biological evaluation of ustiloxin natural products and two analogs. | ||||
Ref 528337 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51. Epub 2006 Jul 25.Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. | ||||
Ref 528428 | J Med Chem. 2006 Sep 21;49(19):5664-70.Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. | ||||
Ref 528474 | J Med Chem. 2006 Oct 19;49(21):6412-5.2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. | ||||
Ref 529270 | Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67. | ||||
Ref 529890 | Liposomal-encapsulated doxorubicin (Myocet; D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study. Tumori. 2008 Sep-Oct;94(5):686-90. | ||||
Ref 530307 | Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. | ||||
Ref 532537 | CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11. | ||||
Ref 533035 | Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. | ||||
Ref 534009 | J Med Chem. 1993 Apr 30;36(9):1146-56.Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin. | ||||
Ref 534060 | J Med Chem. 1993 Mar 5;36(5):544-51.Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)methyl]-1,2,3-trimethoxy-9-(methylthio)-8H- cyclohepta[a]naphthalen-8-ones as novel cytotoxic and antimitotic agents. | ||||
Ref 534469 | J Med Chem. 1997 Sep 12;40(19):3049-56.Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization. | ||||
Ref 534600 | J Med Chem. 1998 Mar 26;41(7):1155-62.Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. | ||||
Ref 534652 | J Med Chem. 1998 Jun 18;41(13):2333-8.Structure-activity requirements for flavone cytotoxicity and binding to tubulin. | ||||
Ref 534765 | J Med Chem. 1998 Dec 3;41(25):4965-72.Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. | ||||
Ref 534776 | Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 1998 Dec 15;37(50):17571-8. | ||||
Ref 534795 | Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000.Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. | ||||
Ref 536411 | Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36. | ||||
Ref 536504 | Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics. 2007 May-Jun;4(3):197-209. | ||||
Ref 536891 | Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26. Epub 2008 Oct 16. | ||||
Ref 537193 | Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. Epub 2009 Mar 29. | ||||
Ref 543674 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). | ||||
Ref 544311 | An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971. | ||||
Ref 550022 | Microtubule assembly protects the region 28-38 of the beta- tubulin subunit. Article first published online: 4 FEB 2005. | ||||
Ref 550066 | Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 11/2006; 16(19):5164-8. | ||||
Ref 551628 | Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.